Breaking News, Collaborations & Alliances

Charles River, FOXG1 Research Foundation Partner to Advance Rare Disease Gene Therapy Development

Charles River will help advance the FRF’s gene therapy through clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International, Inc. has partnered with the FOXG1 Research Foundation (FRF), a parent-led global organization driving the research to cure FOXG1 syndrome and related neurological disorders, to drive drug development through the clinical phase. FRF will collaborate with Charles River in a comprehensive gene therapy contract development and manufacturing organization (CDMO) agreement. FOXG1 syndrome is a severe rare neurological genetic disorder that greatly impacts e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters